← Back to Clinical Trials
Recruiting NCT05700318

NCT05700318 Study Using the ShiraTronics Migraine Therapy System

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05700318
Status Recruiting
Phase
Sponsor ShiraTronics
Condition Chronic Migraine, Headache
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2023-05-05
Primary Completion 2025-03

Eligibility & Interventions

Sex All sexes
Min Age 22 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
neurostimulator

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2023-05-05 with a primary completion date of 2025-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this pilot study is to assess the preliminary safety and efficacy of the ShiraTronics Migraine Therapy System in prophylactic treatment of patients with refractory chronic migraine.

Eligibility Criteria

Inclusion Criteria: 1. Participants who are 22 years of age or older. 2. History of migraine ≥ 12 months. 3. Participants experiencing between 15 to 26 headache days per month, with at least 8 headache days (per month) with migraine phenotype presentation. 4. Inadequate response to, unwilling, or contraindicated to Onabotulinumtoxin A and CGRP monoclonal antibodies therapy. 5. Stable use of migraine medication. Exclusion Criteria: 1. Post-traumatic headache. 2. Medication overuse headache. 3. New daily persistent headache. 4. Report experiencing unremitting, continuous headaches with no relief. 5. Previously implanted neurostimulator to treat headache. 6. History of cervical radiofrequency ablation or had any other intervention/device for migraine.

Contact & Investigator

Central Contact

Fred Ecklund

✉ fecklund@shiratronics.com

📞 1-844-228-7330

Principal Investigator

Scientific Advisory Board

STUDY DIRECTOR

ShiraTronics

Frequently Asked Questions

Who can join the NCT05700318 clinical trial?

This trial is open to participants of all sexes, aged 22 Years or older, studying Chronic Migraine, Headache. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05700318 currently recruiting?

Yes, NCT05700318 is actively recruiting participants. Contact the research team at fecklund@shiratronics.com for enrollment information.

Where is the NCT05700318 trial being conducted?

This trial is being conducted at Broadmeadow, Australia, Hurstville, Australia, Wayville, Australia, Perth, Australia.

Who is sponsoring the NCT05700318 clinical trial?

NCT05700318 is sponsored by ShiraTronics. The principal investigator is Scientific Advisory Board at ShiraTronics. The trial plans to enroll 40 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology